Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer and CX-072 Abstract – Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.
ASCO2020
CX-2009
https://meetinglibrary.asco.org/record/188112/abstractPROCLAIM-
CX072
https://meetinglibrary.asco.org/record/186711/abstract
Â